Holen Sie sich die Stockscreener-App
182.94
1.76%
-3.27
Handel nachbörslich:
182.94
Schlusskurs vom Vortag:
$186.21
Offen:
$186.97
24-Stunden-Volumen:
229.72K
Relative Volume:
0.37
Marktkapitalisierung:
$9.22B
Einnahmen:
$338.46M
Nettoeinkommen (Verlust:
$-310.96M
KGV:
-28.02
EPS:
-6.53
Netto-Cashflow:
$-132.82M
1W Leistung:
+1.16%
1M Leistung:
+3.46%
6M Leistung:
+73.85%
1J Leistung:
+39.06%
1-Tages-Spanne:
$182.69
$186.97
1-Wochen-Bereich:
$178.00
$187.18
52-Wochen-Spanne:
$86.99
$191.50
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Firmenname
Axsome Therapeutics Inc
Sektor
Branche
Telefon
(212) 332-3241
Adresse
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
182.94 | 9.39B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | Eingeleitet | B. Riley Securities | Buy |
| 2025-09-03 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-07 | Eingeleitet | Jefferies | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-31 | Bestätigt | Mizuho | Outperform |
| 2024-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-04-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2024-01-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-08-08 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Eingeleitet | Piper Sandler | Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2022-09-07 | Fortgesetzt | Mizuho | Buy |
| 2021-08-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Eingeleitet | Berenberg | Buy |
| 2021-01-08 | Eingeleitet | Jefferies | Buy |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-09-29 | Eingeleitet | BofA Securities | Underperform |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-14 | Eingeleitet | Cowen | Outperform |
| 2019-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-16 | Bestätigt | Guggenheim | Buy |
| 2019-10-16 | Eingeleitet | Guggenheim | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-28 | Eingeleitet | SunTrust | Buy |
| 2019-05-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-08 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-15 | Bestätigt | H.C. Wainwright | Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2015-12-15 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Why (AXSM) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Axsome Therapeutics (AXSM) Stock Analysis: A 63% Revenue Growth Fuels a Promising Biotech Play - DirectorsTalk Interviews
Morgan Stanley Remains Bullish on Axsome (AXSM), Reiterates $190 PT - MSN
Should You Buy Axsome Therapeutics Stock Before Feb. 23? - AOL.com
Auvelity Priority Review And Revenue Update Could Be A Game Changer For Axsome Therapeutics (AXSM) - Sahm
Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Axsome Therapeutics Stock Soars 75% Amid Strong Growth - Intellectia AI
Principal Financial Group Inc. Acquires 12,923 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Hot Picks: Small-cap pharma stocks in focus as key drug approvals near - BNN Bloomberg
The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Strong Auvelity Sales And Alzheimer’s Label Hopes - Yahoo Finance
Axsome Therapeutics says AXS-12 NDA submission on track for January - MSN
1 High-Flying Stock With More Upside Ahead - Finviz
Axsome Therapeutics (AXSM) Reports 66% Revenue Growth in FY2025, Beats Analyst Estimates - Finviz
Axsome Therapeutics (NASDAQ:AXSM) Given New $245.00 Price Target at Jefferies Financial Group - MarketBeat
Axsome Therapeutics (AXSM) reports 66% revenue growth in FY2025, beats analyst estimates - MSN
Axsome Therapeutics, Inc. (AXSM) Investor Outlook: Strong Buy Ratings and Promising 15.71% Potential Upside - DirectorsTalk Interviews
Axsome Therapeutics (NASDAQ:AXSM) CEO Sells $6,015,296.00 in Stock - MarketBeat
Axsome Therapeutics CEO Tabuteau sells $6.0m in shares By Investing.com - Investing.com Canada
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN
Axsome Therapeutics AXS-05 Alzheimer's Launch Could Drive Upside, RBC Says - marketscreener.com
Axsome Therapeutics stock maintains Outperform rating at RBC on ADA approval potential - Investing.com Canada
Understanding Momentum Shifts in (AXSM) - Stock Traders Daily
Top Investors’ Stock Portfolio: 10 Mid-cap Stocks To Buy - Insider Monkey
J. Safra Sarasin Holding AG Has $1.08 Million Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
AXSM: Leerink Partners Raises Price Target to $205, Maintains Ou - GuruFocus
Leerink Partners Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - MarketBeat
Revenues Tell The Story For Axsome Therapeutics, Inc. (NASDAQ:AXSM) - 富途牛牛
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23 - The Manila Times
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026 - Quiver Quantitative
Is Axsome Therapeutics Inc attractive for institutional investors2025 Volatility Report & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026? - sharewise.com
Universal Beteiligungs und Servicegesellschaft mbH Increases Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Cabot Wealth Management Inc. Buys Shares of 5,560 Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Axsome Therapeutics: A Conditional Buy Built On SG&A Discipline (NASDAQ:AXSM) - Seeking Alpha
Ari Maizel, chief commercial officer of Axsome, sells $1.38m in shares By Investing.com - Investing.com Nigeria
Ari Maizel, chief commercial officer of Axsome, sells $1.38m in shares - Investing.com UK
Pizzie, Axsome Therapeutics CFO, sells $2.25m in shares By Investing.com - Investing.com Canada
Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) Insider Sells 7,500 Shares of Stock - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) CFO Sells $2,255,040.00 in Stock - MarketBeat
How The New Price Target Is Shaping The Axsome Therapeutics (AXSM) Investment Story - Yahoo Finance
MoneyShow Top Picks 2026: Axsome Therapeutics Inc. (AXSM) - Barchart.com
Analysts Conflicted on These Healthcare Names: Hinge Health, Inc. Class A (HNGE), Axsome Therapeutics (AXSM) and TG Therapeutics (TGTX) - The Globe and Mail
Assessing Axsome Therapeutics (AXSM) Valuation After Analyst Upgrades And Pipeline Progress - Yahoo Finance
Axsome begins phase III AXS-14 Forward trial for fibromyalgia management - MSN
(01/23/26) Top Picks 2026: Axsome Therapeutics Inc. (AXSM) - moneyshow.com
Piper Sandler Bullish on Axsome Therapeutics (AXSM) Ahead of Likely Auvelity Label Expansion by April 30 - Insider Monkey
FY2025 Earnings Forecast for AXSM Issued By HC Wainwright - MarketBeat
Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):